核心技术平台进展 - 公司宣布其专有PredicTcell™平台取得重大进展，该平台旨在通过先进的机器学习和基于Transformer的模型加速精准免疫疗法的开发与提升疗效 [1] - 平台的开发获得了微软和Databricks的支持，利用其先进的云和数据技术以实现可扩展性和效率 [1] - PredicTcell Alpha版本使用基于Transformer的架构训练了超过124,000条记录，使用传统机器学习架构训练了91,000条记录 [2] - Alpha模型的召回率水平达到约92%–97%，精确度范围约为38%–43%，验证了AI驱动预测免疫活性肽-T细胞受体相互作用的可行性 [2] Beta版本数据规模与模型优化 - PredicTcell Beta版本将训练数据集扩展至约140万条，总数据集超过67亿条记录 [5] - 训练数据集扩大了十倍至约140万条，而总数据集增长了超过100倍至超过67亿条 [6] - 为构建训练集分析了超过107亿个数据点，包括65亿个病毒学数据点、42亿个基因组学数据点和4.16亿个肿瘤学数据点 [6] - 模型训练的特征数量从22个扩展到27个 [6] 潜在治疗突破与行业影响 - 基于公司专有ExacTcell™平台的见解和积极的1期试验结果，PredicTcell Beta旨在显著提高识别病毒学靶点的精确度 [3] - 通过大幅扩展数据管道和微调模型，未来的T细胞疗法可能几乎每次都能准确结合预期靶点，这将显著提高成功概率 [3][5] - 此类可预测性将是医学领域的变革性突破，意味着临床成功率大幅提高、开发时间线缩短、药物成本降低以及更多患者能够获得拯救生命的疗法 [3][6] - 公司的人工智能计划旨在提高基于T细胞的疗法的疗效标准，降低开发成本，并解锁免疫疗法全新的市场 [3]

Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Commu ...

MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events: Drug Discovery Innovation Programme, September 25-26Location: Intercontinental Hotel, Barcelona, Spain Paris Midcap Event 2025, September 30-October 1Location: Four Seasons George V, Paris, France BME Investor Access Event 202 ...

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CNM-Au8® improved the brain’s energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Expanded Disabi ...

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil drypowder. ...

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company†or "Anebulo†), today announces the first subjects dosed in its Phase 1 single ascending dose ("SAD†) study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjec. ...

公司核心动态 - MiNK Therapeutics公司总裁兼首席执行官Jennifer Buell博士将在2025年9月23日至26日于波士顿举行的第十届CAR-TCR峰会上发表主题演讲[1] - Buell博士将在题为“审视细胞疗法在肿瘤学之外的范畴并回顾成功与失败”的全体会议上发言[2] - 发言内容将首次公布公司iNKT平台的人体数据 展示其在严重免疫衰竭中实现持久的疾病逆转和无类固醇缓解[2] - 公司将阐述其转化战略 重点介绍精准试验设计、患者分层和组织特异性靶向如何加速高负担非肿瘤适应症的开发[2] 公司技术与产品管线 - MiNK Therapeutics是一家临床阶段生物制药公司 专注于开发同种异体不变自然杀伤T细胞疗法和精准靶向免疫技术[5] - 公司专有平台旨在恢复免疫平衡 并在癌症、免疫介导疾病和肺部免疫衰竭中驱动细胞毒性免疫反应[5] - 主导在研产品agenT-797是一种现成的同种异体iNKT细胞疗法 目前正针对移植物抗宿主病、实体瘤和严重肺部免疫衰竭进行临床开发[5] - 公司同时推进基于T细胞受体的疗法和新生抗原发现工具管线 这些工具能够实现肿瘤和组织特异性免疫激活 具有广泛的应用潜力[5] - 公司的iNKT疗法采用现成方法 设计为可扩展、广泛可及 且无需HLA匹配或淋巴细胞清除即可使用[3] 行业会议与平台价值 - 第十届CAR-TCR峰会是细胞疗法领域首要的全球论坛 汇聚超过800名利益相关者 包括C级高管、顶尖科学家、投资者和监管机构[4] - 会议拥有100多名世界级演讲嘉宾和六个并行内容轨道 涵盖从发现到商业化的全过程[4] - 该峰会是工程化细胞疗法领域权威的全球性会议 展示CAR-T、TCR和iNKT细胞疗法在肿瘤学、自身免疫病等领域的最新突破[2][4]

MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Gue ...

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response against pathological f ...

The company’s leading drug candidate, RMC-6236, also called daraxonrasib, made headlines recently when the company released a set of clinical trial results that support initiating the RASolute 303 global Phase 3 registrational trial of the drug as a treatment for first-line metastatic pancreatic ductal adenocarcinoma. This is a particularly dangerous form of pancreatic cancer, and existing treatments have, at best, limited efficacy.It’s not an easy approach, however. RAS mutations occur in about one-third o ...